RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
Patients with castration-refractory prostate cancer (PC) are a complicated group of patients for treatment. At the time of diagnosis, 85% of patients have a localized tumor process, however, in 40% of patients, generalization of the tumor process is observed. The most common localization of prostate...
Saved in:
Main Authors: | A. A. Kostin, A. G. Muradyan, A. O. Tolkachev, S. V. Popov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
QUASAR, LLC
2017-12-01
|
Series: | Исследования и практика в медицине |
Subjects: | |
Online Access: | https://www.rpmj.ru/rpmj/article/view/223 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer
by: Vera Höllriegl, et al.
Published: (2021-06-01) -
analysis of radon and radium content in springs of ekaterinburg city and its settlements
by: Vladimir S. Semenishchev, et al.
Published: (2021-10-01) -
Theoretical Study of the Quadruple Gamma Transitions of Radioactive Radon and Radium Isotopes Based on Half-Life
by: Duaa Abed Salim, et al.
Published: (2024-12-01) -
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis
by: Nobuaki Matsubara, et al.
Published: (2025-01-01) -
Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)